Eurostat: Cyprus Lowest Breast Cancer Screening Participation in EU
Cancer Screening Rates in Europe: A Look at cyprus
Table of Contents
Updated November 2, 2025
Key Findings from Eurostat Data
Recent data published by Eurostat in October 2023, coinciding with Breast Cancer awareness Month, reveals significant disparities in cancer screening participation across teh European Union. These differences highlight varying levels of access to preventative healthcare and public awareness.
breast Cancer Screening Participation
In 2023, the EU average for breast cancer screening participation among women aged 50-69 was approximately 65%. However, Cyprus reported a participation rate of only 29.8%, placing it second from last within the EU. Leading countries in breast cancer screening included Denmark (83.3%),Sweden (83.0%), and finland (81.5%), while Greece (14.5%) had the lowest rate, followed by Cyprus and Latvia (36.1%).
Cervical cancer Screening Rates
For cervical cancer screening among women aged 20-64, the EU average participation rate is around 55%. Cyprus, with a rate of approximately 48%, falls below this average, indicating a need for increased outreach and improved access to screening programs. Denmark and Slovenia demonstrate the highest participation rates, both exceeding 65%, while Poland and Slovakia lag behind, with rates below 40%.
Colorectal Cancer screening Participation
Regarding colorectal cancer screening for individuals aged 50-74, the EU average participation rate is about 45%.Cyprus records a participation rate of around 40%, which, while lower than the EU average, shows a positive trend of gradual improvement in recent years. Finland and Ireland lead in this area,with participation rates exceeding 60%,while Romania and bulgaria remain below 30%.
Factors Influencing Participation
The observed gaps in screening participation are largely attributed to a combination of factors, including insufficient public awareness, limited access to specialized healthcare facilities, and organizational challenges within national prevention systems.Addressing these issues is crucial for improving cancer prevention outcomes across Europe.